BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29844307)

  • 1. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.
    Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS
    Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression.
    Cao MX; Zhang WL; Yu XH; Wu JS; Qiao XW; Huang MC; Wang K; Wu JB; Tang YJ; Jiang J; Liang XH; Tang YL
    J Exp Clin Cancer Res; 2020 Jun; 39(1):102. PubMed ID: 32493454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
    Vergani E; Dugo M; Cossa M; Frigerio S; Di Guardo L; Gallino G; Mattavelli I; Vergani B; Lalli L; Tamborini E; Valeri B; Gargiuli C; Shahaj E; Ferrarini M; Ferrero E; Gomez Lira M; Huber V; Del Vecchio M; Sensi M; Leone BE; Santinami M; Rivoltini L; Rodolfo M; Vallacchi V
    Cell Commun Signal; 2020 Sep; 18(1):156. PubMed ID: 32967672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.
    Nguyen MT; Lin CH; Liu SM; Miyashita A; Ihn H; Lin H; Ng CH; Tsai JC; Chen MH; Tsai MS; Lin IY; Liu SC; Li LY; Fukushima S; Lu J; Ma N
    Neoplasia; 2020 Dec; 22(12):789-799. PubMed ID: 33142243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
    Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
    Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-876-5p represses the cell proliferation and invasion of colorectal cancer through suppressing YAP signalling via targeting RASAL2.
    Ren L; Zhang Z; Feng Y; Luo M; Hao Z
    Clin Exp Pharmacol Physiol; 2020 May; 47(5):867-876. PubMed ID: 31990059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
    Díaz-Martínez M; Benito-Jardón L; Alonso L; Koetz-Ploch L; Hernando E; Teixidó J
    Cancer Res; 2018 Feb; 78(4):1017-1030. PubMed ID: 29229605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
    Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
    EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
    Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.
    Yang C; Wu K; Wang S; Wei G
    J Cell Biochem; 2018 Jul; 119(7):5646-5656. PubMed ID: 29384226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
    Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circular RNA circCCDC85A inhibits breast cancer progression via acting as a miR-550a-5p sponge to enhance MOB1A expression.
    Meng L; Chang S; Sang Y; Ding P; Wang L; Nan X; Xu R; Liu F; Gu L; Zheng Y; Li Z; Sang M
    Breast Cancer Res; 2022 Jan; 24(1):1. PubMed ID: 34983617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
    Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-590-5p Inhibits Intestinal Inflammation by Targeting YAP.
    Yu M; Luo Y; Cong Z; Mu Y; Qiu Y; Zhong M
    J Crohns Colitis; 2018 Jul; 12(8):993-1004. PubMed ID: 29912317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-873-5p inhibits the progression of colon cancer via repression of tumor suppressor candidate 3/AKT signaling.
    Zhu Y; Zhang X; Qi M; Zhang Y; Ding F
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2126-2134. PubMed ID: 31039290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
    Kim JH; Ahn JH; Lee M
    Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
    Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2.
    Liu SM; Lu J; Lee HC; Chung FH; Ma N
    Oncotarget; 2014 Oct; 5(19):9444-59. PubMed ID: 25275294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.